Human apolipoprotein B. Evidence for its immunochemical heterogeneity using monoclonal antibodies and an immunoenzymometric assay.
Predefined monoclonal antibodies (Mabs) were used in an immunoenzymometric assay to study the immunochemical heterogeneity of lipoproteins and to search for potential epitopes with pathological importance. By measuring apolipoprotein B (apo B) epitopes in patients with and without angiographically documented coronary artery disease and in patients with type IIa hyperlipoproteinemia, we have found that both types of patients have a significant increase in Apo B-containing particles specifically recognized by one Mab (BL3). We have also observed that the effects of fenofibrate on type IIa patients vary greatly depending on the plasma concentrations of various Apo B-containing lipoproteins. The greatest effects occurred in patients with epitopes recognized by BL3. Lastly, by sequential precipitation of specific epitopes by BL3, we have obtained evidence that the residual epitope(s) may be related to one or more lipoprotein particles.
Luyeye
I
I
Service de Recherche sur les Lipoproteines et l'Athérosclérose, Institut Pasteur, Lille, France.
Fievet
C
C
Dupont
J C
JC
Durieux
C
C
Slimane
N
N
Lecocq
J F
JF
Demarquilly
C
C
Fruchart
J C
JC
D000911:Antibodies, Monoclonal; D001055:Apolipoproteins B / Q000097:blood*; D000939:Epitopes / Q000032:analysis; D011345:Fenofibrate / Q000494:pharmacology; D006801:Humans; D007124:Immunoenzyme Techniques
D000911:Antibodies, Monoclonal; D001055:Apolipoproteins B; D000939:Epitopes; D011345:Fenofibrate